Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › DNA Medicine Institute Wins $1.5M NIH Grant to Develop Point-of-Care Factor VIII, Hemlibra Test

DNA Medicine Institute Wins $1.5M NIH Grant to Develop Point-of-Care Factor VIII, Hemlibra Test

Oct 12, 2020
|
staff reporter

NEW YORK — Medical technology incubator The DNA Medicine Institute last month was awarded a $1.5 million grant from the National Institutes of Health to develop a rapid, point-of-care fingerstick blood-based test for Factor VIII (FVIII) and Roche's hemophilia A treatment emicizumab (Hemlibra).

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Apr
16
Featured Webinar

The Post-Vaccine COVID Testing Landscape: A Virtual Roundtable Discussion

Sponsored by
Thermo Fisher Scientific

With COVID-19 vaccines rolling out, clinical labs and test developers are preparing for changes in both demand for testing and types of testing for SARS-CoV-2.

May
10
Featured Webinar

Predicting COVID-19 Severity: Leveraging the Host Immune Response to Identify High-Risk Patients and Improve Outcomes

Sponsored by
MeMed

Amid the COVID-19 pandemic, hospitals and intensive care units around the world have been overwhelmed by unprecedented levels of demand. 

May
13
Featured Webinar

Limits of Detection Matter: New Challenges for SARS-CoV-2 Diagnostics and COVID-19 Patient Management

Sponsored by
LGC SeraCare Life Sciences

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.

What's Popular?

In Point-of-Care Testing

  1. Australian Firm AnteoTech Obtains CE Marking for COVID-19 Antigen Test, Reader

  2. Siemens Healthineers Gets CE Mark for Point-of-Care High-Sensitivity Cardiac Troponin I Test

  3. Lucira Health Nabs OTC EUA for SARS-CoV-2 Test, Expects Q1 Revenues of up to $4.5M

  4. CLIA Waiver in Hand, Binx Health Targeting Retailers, Urgent Care Centers With STI Tests

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.